The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the ‘Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19’
Open Access
- 21 November 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (46), 4389-4390
- https://doi.org/10.1093/eurheartj/ehaa935
Abstract
The results of the "Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19” have been pubblished in the New England Journal of Medicine. https://www.nejm.org/doi/10.1056/NEJMoa2022926.Keywords
This publication has 4 references indexed in Scilit:
- The RECOVERY PlatformThe New England Journal of Medicine, 2021
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19The New England Journal of Medicine, 2020
- Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions revealInternational Journal of Antimicrobial Agents, 2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)Jama-Journal Of The American Medical Association, 2020